MedTrace Logo

Absolute Bioavailability Study With Ipragliflozin

NCT01611428 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-06-05

No results posted yet for this study

Summary

A study to assess the absolute bioavailability of ipragliflozin in healthy subjects.

Conditions

  • Bioavailability of Ipragliflozin
  • Healthy Subjects

Interventions

DRUG

Ipragliflozin

Oral and Intravenous (i.v.)

Sponsors & Collaborators

  • Astellas Pharma Europe B.V.

    lead INDUSTRY

Principal Investigators

  • Clinical Study Manager · Astellas Pharma Europe B.V.

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01611428 on ClinicalTrials.gov